These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 22338149

  • 21. [Efficacy and safety of low-dose rituximab combined with different dosage of glucocorticoids for immune thrombocytopenia].
    Xing WW, Li ZY, Yan ZL, Liu KG, Li N, Cao J, Pan XY, He XP, Xu KL.
    Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):409-12. PubMed ID: 23688751
    [Abstract] [Full Text] [Related]

  • 22. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
    Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA.
    J Clin Oncol; 2006 Aug 20; 24(24):3880-6. PubMed ID: 16864854
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. High dose dexamethasone therapy shows better responses in acute immune thrombocytopenia than in chronic immune thrombocytopenia.
    Naithani R, Mahapatra M, Kumar R, Mishra P, Saxena R.
    Platelets; 2010 Aug 20; 21(4):270-3. PubMed ID: 20218911
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia.
    Mahévas M, Ebbo M, Audia S, Bonnotte B, Schleinitz N, Durand JM, Chiche L, Khellaf M, Bierling P, Roudot-Thoraval F, Godeau B, Michel M.
    Am J Hematol; 2013 Oct 20; 88(10):858-61. PubMed ID: 23798363
    [Abstract] [Full Text] [Related]

  • 27. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
    Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Dürk H, Rost A, Neise M, von Grünhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS.
    J Clin Oncol; 2005 May 20; 23(15):3383-9. PubMed ID: 15908650
    [Abstract] [Full Text] [Related]

  • 28. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, Fanin R.
    Haematologica; 2002 Feb 20; 87(2):189-95. PubMed ID: 11836170
    [Abstract] [Full Text] [Related]

  • 29. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia.
    Gómez-Almaguer D, Tarín-Arzaga L, Moreno-Jaime B, Jaime-Pérez JC, Ceballos-López AA, Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Sánchez-Cárdenas M.
    Eur J Haematol; 2013 Jun 20; 90(6):494-500. PubMed ID: 23470153
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of rituximab treatment in Indian pemphigus patients.
    Kanwar AJ, Tsuruta D, Vinay K, Koga H, Ishii N, Dainichi T, Hashimoto T.
    J Eur Acad Dermatol Venereol; 2013 Jan 20; 27(1):e17-23. PubMed ID: 22176540
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 20; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
    Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group).
    Haematologica; 2008 Dec 20; 93(12):1829-36. PubMed ID: 18945747
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K, Prins C, Saurat JH, French LE.
    Br J Dermatol; 2006 Dec 20; 155(6):1197-200. PubMed ID: 17107389
    [Abstract] [Full Text] [Related]

  • 38. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.
    Maung SW, Leahy M, O'Leary HM, Khan I, Cahill MR, Gilligan O, Murphy P, McPherson S, Jackson F, Ryan M, Hennessy B, McHugh J, Goodyer M, Bacon L, O'Gorman P, Nee A, O'Dwyer M, Enright H, Saunders J, O'Keeffe D.
    Br J Haematol; 2013 Oct 20; 163(1):118-22. PubMed ID: 23909468
    [Abstract] [Full Text] [Related]

  • 39. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, Kentos A, Pierre P, Boulet D, Bries G, Lê PQ, Janssens A, Delannoy A.
    J Intern Med; 2009 Nov 20; 266(5):484-91. PubMed ID: 19549092
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.